SUPN SUPERNUS PHARMACEUTICALS, INC.companySEC Filings & Insider Trading Activity 2026
Latest SUPERNUS PHARMACEUTICALS, INC. (SUPN) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 2, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on April 22, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for SUPERNUS PHARMACEUTICALS, INC. (SUPN) (SEC CIK 1356576), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: pharmaceutical development and commercialization of prescription drugs
- • New emphasis on compliance with 2025 Executive Orders targeting drug price transparency, expanded Medicare negotiations, and site-neutral payment policies
Risk Factors
- • Legal risk from potential claims or fines related to 2021 ransomware attack, fines or costs not yet estimable
- • Operational risk from increased ongoing IT security investments initiated post-2021 ransomware incident
Management Discussion & Analysis
- • Total revenues $718.95M, up 9% YoY from $661.82M driven by Qelbree $304.65M (+26%) and new launch ONAPGO $17.25M
- • Operating loss driven by SG&A $485.56M (51% increase YoY) and intangible amortization $89.46M (+15%); net loss ($38.55M) vs net income $73.87M in 2024
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • Revenue data and YoY comparison not provided in text
- • No profitability or margin figures disclosed in section
Risk Factors
- • New tariff risk due to recent US tariffs on pharmaceuticals, possibly increasing import and vendor costs, currently assessing financial impact
- • Legal risk materially updated: multiple litigation matters post-Sage acquisition, including securities class action, SEC subpoena, derivative litigation, and stockholder complaints in 2025
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • CEO Khattar base salary raised 3% to $1,067,100; 2025 bonus $846,930; granted 341,610 options + 204,966 PSUs
- • CFO Dec salary raised ~4% to $525,100; 2025 bonus $233,894; granted 17,500 options, 3,000 RSUs, 3,500 PSUs
Annual Reports Archive10-K
AI-powered analysis of SUPERNUS PHARMACEUTICALS, INC. (SUPN) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of SUPERNUS PHARMACEUTICALS, INC. (SUPN) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of SUPERNUS PHARMACEUTICALS, INC. (SUPN) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $667.2M | $607.5M | $661.8M | $719.0M |
| Operating Income | $46.1M | -$5.3M | $81.7M | -$62.3M |
| Net Income | $60.7M | $1.3M | $73.9M | -$38.5M |
| Op. Margin | 6.9% | -0.9% | 12.3% | -8.7% |
| Net Margin | 9.1% | 0.2% | 11.2% | -5.4% |
| Balance Sheet | ||||
| Total Assets | $1.7B | $1.3B | $1.4B | $1.5B |
| Equity | $886.2M | $921.5M | $1.0B | $1.1B |
| ROE | 6.9% | 0.1% | 7.1% | -3.6% |
Source: XBRL financial data from SUPERNUS PHARMACEUTICALS, INC. (SUPN) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 22, 2026 | — | — | — |
8-K | Apr 7, 2026 | — | — | — |
10-K | Mar 2, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 24, 2026 | — | Analysis | — |
8-K | Feb 24, 2026 | — | Analysis | — |
8-K | Feb 12, 2026 | — | — | |
8-K | Jan 28, 2026 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Feb 25, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 4, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | May 8, 2024 | Mar 31, 2024 | — | |
10-K | Feb 27, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 8, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 8, 2023 | Jun 30, 2023 | — | |
10-Q | May 9, 2023 | Mar 31, 2023 | — | |
10-K | Mar 9, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 9, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 8, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-K | Apr 13, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 5, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 6, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest SUPN SEC filings in 2026?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) has filed a 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on April 22, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did SUPN file its most recent 10-K annual report?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed its most recent 10-K annual report on March 2, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view SUPN 10-Q quarterly reports?
SUPERNUS PHARMACEUTICALS, INC. (SUPN)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every SUPN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has SUPN filed recently?
SUPERNUS PHARMACEUTICALS, INC. (SUPN)'s most recent 8-K was filed on April 22, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find SUPN insider trading activity (Form 4)?
SignalX aggregates every SUPN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does SUPN file with the SEC?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new SUPN filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
What is SUPN's SEC CIK number?
SUPERNUS PHARMACEUTICALS, INC. (SUPN)'s SEC CIK (Central Index Key) number is 1356576. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1356576 to look up all SUPN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find SUPN return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from SUPERNUS PHARMACEUTICALS, INC. (SUPN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of SUPERNUS PHARMACEUTICALS, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 56+ filings.